All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The standard myeloablative conditioning regimen (MAC) for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) is busulfan (BUS) or total body irradiation (TBI) in combination with cyclophosphamide (Cy). More recently, fludarabine (Flu) has been investigated as an alternative to cyclophosphamide to lessen regimen toxicity. Treosulfan, an analogue to busulfan, has also been investigated as an alternative to improve efficacy.
At the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the safety and efficacy of conditioning combinations were evaluated for patients undergoing allo-HSCT, using data from the Acute Leukemia Working Party (ALWP) of the EBMT. We summarize results from four key talks below.
Ryszard Swoboda presented a retrospective study1 comparing a combination of fludarabine with the standard myeloablative regimens of either TBI at 12 Gy (FluTBI12) or intravenous busulfan (FB4) before allo-HSCT (Figure 1).
Figure 1. Study design*
Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; CR1, first complete remission; CR2, second complete remission; FB4, busulfan intravenous at a dose of 12.8 mg/kg (4 days) plus fludarabine; FluTBI12, fludarabine with total body irradiation at a dose of 12 Gy; HLA, human leukocyte antigen; MSD, matched sibling donor; UD, unrelated donor.
*Adapted from Swoboda et al.1
†Patients were exactly matched for cytogenetic risk groups, disease status at allo-HSCT (CR1/CR2), donor type (MSD, UD), and stem cell source (peripheral blood/bone marrow).
Table 1. Patient characteristics*
Characteristic |
FluTBI12 |
FB4 |
---|---|---|
Median age, years (range) |
41 (18.2–61.8) |
41.4 (18.7–67.4) |
Male/Female, % |
61.5/38.5 |
62.4/37.6 |
Cytogenetic risk group, % |
||
Standard |
8.3 |
8 |
Intermediate |
41.3 |
42.3 |
High |
11.9 |
11.7 |
Unknown |
38.5 |
38 |
In CR1 at transplantation, % |
78 |
78.9 |
Median year of transplantation (range) |
2017 (2009–2020) |
2016 (2009–2020) |
Donor type, % |
||
HLA-identical sibling |
32.4 |
27.7 |
10/10 HLA-matched unrelated |
54.1 |
51.4 |
9/10 HLA-mismatched unrelated |
13.5 |
20.8 |
CR1, first complete remission; FB4, busulfan intravenous at a dose of 12.8 mg/kg (4 days) plus fludarabine; FluTBI12, fludarabine with total body irradiation at 12 Gy; HLA, human leukocyte antigen. |
Table 2. Efficacy and toxicity results of FluTBI12 versus FB4*
Parameter, % |
FluTBI12 |
FB4 |
HR (95% CI) |
---|---|---|---|
Relapse incidence |
19.2 |
29.4 |
1.55 (0.9–2.66) |
Nonrelapse mortality |
15.6 |
10.9 |
0.62 (0.34–1.15) |
Leukemia-free survival |
65.2 |
59.8 |
1.1 (0.73–1.67) |
Overall survival |
69.7 |
72.1 |
0.96 (0.61–1.52) |
GvHD-free, relapse-free survival |
48.5 |
48.5 |
0.95 (0.67–1.36) |
Acute GvHD grade |
|||
2–4 |
17.8 |
24.4 |
1.49 (0.86–2.6) |
3–4 |
7.5 |
6 |
0.83 (0.34–2.07) |
Chronic GvHD |
41.8 |
34.3 |
0.77 (0.52–1.15) |
Extensive chronic GvHD |
16.4 |
15.9 |
0.96 (0.52–1.78) |
FB4, busulfan intravenous at a dose of 12.8 mg/kg (4 days) plus fludarabine; FluTBI12, fludarabine with total body irradiation at 12 Gy; GvHD, graft-versus-host disease. |
In summary, FluTBI12 and FB4 produced comparable efficacy and toxicity in adult patients receiving allo-HSCT. Swoboda et al.1 highlighted that the regimen choice should be guided based on patient history, availability of TBI, and experience of the centers using MAC.
Sebastian Giebel presented results from a retrospective study2 comparing the safety and efficacy of FluTBI12 versus cyclophosphamide plus TBI at 12 Gy (CyTBI12).
The study design is depicted in Figure 2.
Figure 2. Study design*
allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; CR1, first complete remission; CR2, second complete remission; CyTBI12, cyclophosphamide plus total body irradiation at 12 Gy; FluTBI12, fludarabine plus total body irradiation at 12 Gy; MSD, matched sibling donor; UD, unrelated donor.
*Adapted from Giebel et al.2
†Patients were exactly matched for cytogenetic risk groups, disease status at allo-HSCT (CR1/CR2), donor type (MSD, UD), and stem cell source (peripheral blood/bone marrow).
Patient characteristics are shown in Table 3. The only significant difference was found between the median year of transplantation (p < 0.0001).
Table 3. Patient characteristics*
Characteristic |
FluTBI12 |
CyTBI12 |
---|---|---|
Median age, years (range) |
38 (18–69) |
40 (18–60) |
Cytogenetic risk group, % |
||
Standard |
8 |
8 |
Intermediate |
35 |
35 |
High |
13 |
13 |
Unknown |
44 |
44 |
In CR1 at transplantation, % |
78 |
78 |
Median year of transplantation (range) |
2016 (2009–2020) |
2012 (2009–2020) |
Donor type, % |
||
HLA-identical sibling |
37 |
32.5 |
10/10 HLA-matched unrelated |
51 |
54 |
9/10 HLA-mismatched unrelated |
11 |
14 |
CR1, first complete remission; CyTBI12, cyclophosphamide plus total body irradiation at 12 Gy; FluTBI12, fludarabine with total body irradiation at 12 Gy; HLA, human leukocyte antigen. |
There was no significant difference in leukemia-free survival (LFS), overall survival (OS), relapse incidence, nonrelapse mortality (NRM), chronic graft-versus-host disease (GvHD), or GvHD-free/relapse-free survival (GRFS) between conditioning regimens (Figure 3).
Figure 3. Survival outcomes*
aGvHD, acute graft-versus-host disease; cGvHD, chronic graft-versus-host disease; CyTBI12, cyclophosphamide plus total body irradiation at 12 Gy; LFS, leukemia-free survival; FluTBI12, fludarabine plus total body irradiation at 12 Gy; OS, overall survival; NRM, nonrelapse mortality.
*Adapted from Giebel et al.2
There was a significant difference found in acute GvHD (aGvHD) incidence with patients receiving CyTBI12 experiencing higher rates of aGvHD (p = 0.005).
In summary, the data demonstrate that fludarabine is a valid substitute for cyclophosphamide in TBI containing conditioning regimens, with encouraging LFS and OS rates and, importantly, a lower incidence of Grade 2–4 aGvHD.
Treosulfan is an analogue of busulfan that has shown favorable outcomes when substituted for its counterpart in patients with AML/myelodysplastic syndromes (MDS) at mixed doses. However, conditioning with FB4 (fludarabine at 150 or 160 mg/m2 and busulfan at 12.8 mg/kg) was superior to FT14 (fludarabine at 150 or 160 mg/m2 and treosulfan at 42 g/m2) in younger patients (<55 years) with AML in complete remission. Eleni Gavriilaki presented results from a retrospective study3 comparing FB4 with FT14 in patients with relapsed/refractory AML. The study design is summarized in Figure 4.
Figure 4. Study design*
Allo-HSCT, allogeneic hematopoietic stem cell transplant; FB4, fludarabine at 150 or 160 mg/m2 and busulfan at 12.8 mg/kg; FT14, fludarabine at 150 or 160 mg/m2 and treosulfan at 42 g/m2.
*Adapted from Gavriilaki et al.3
Patient characteristics are shown in Table 4.
Table 4. Patient characteristics*
Characteristic |
FT14 |
FB4 |
---|---|---|
Median age, years (range) |
58.1 (21.2–75.9) |
52.4 (18.5–70.7) |
Median follow-up, months |
32.93 |
24.91 |
Adverse cytogenetics, % |
23 |
16.7 |
Time diagnosis to HSCT, median in months (range) |
6.9 (0.5–147.2) |
5.9 (0.3–66.2) |
Cell source, % |
||
Bone marrow |
3.5 |
9 |
Peripheral blood |
96.5 |
91 |
Diagnosis, % |
||
De novo |
69 |
78.5 |
Secondary AML |
31 |
21.5 |
Type of donor, % |
||
MSD |
31 |
44.6 |
UD |
69 |
55.4 |
Median dose of fludarabine, mg/m2 |
150 |
160 |
AML, acute myeloid leukemia; FB4, fludarabine-busulfan; FT14, fludarabine-treosulfan; HSCT, hematopoietic stem cell transplant; MSD, matched sibling donor; UD, unrelated donor. |
Survival outcomes
Table 5. Multivariate analysis*
Factor |
Relapse |
Leukemia-free survival |
Overall survival |
GvHD-free, relapse-free survival |
||||
---|---|---|---|---|---|---|---|---|
HR |
p value |
HR |
p value |
HR |
p value |
HR |
p value |
|
FB4 vs FT14 |
1.83 |
0.01 |
1.52 |
0.012 |
1.65 |
0.009 |
1.48 |
0.03 |
Age |
1.04 |
0.61 |
1.13 |
0.049 |
1.17 |
0.023 |
— |
— |
FB4, fludarabine-busulfan; FT14, fludarabine-treosulfan. |
In line with the previous subset analysis in active AML, treosulfan was associated with superior OS compared with FB4. Notably, the dose of treosulfan used in this study was higher than currently recommended (FT10). Further retrospective studies will be needed to confirm the optimal conditioning regimen.
A treosulfan-based regimen was previously shown to reduce NRM in patients with AML undergoing allo-HSCT from matched sibling donors (MSD) and unrelated donors (UD). Francesco Saraceni presented results from a retrospective study4 investigating whether this improvement was observed for patients undergoing transplant from haploidentical donors, which does not have a standard conditioning regimen. Treosulfan-based (Treo) or thiotepa-busulfan-fludarabine (TBF) conditioning were compared as the preparatory regimens (Figure 5).
Figure 5. Study design*
CR1, first complete remission; CR2, second complete remission; GRFS, GvHD-free, relapse-free survival; GvHD, graft-versus-host disease; haplo-HSCT, haploidentical hematopoietic stem cell transplantation; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; TBF, thiotepa-busulfan-fludarabine; Treo, treosulfan.
*Adapted from Saraceni et al.4
Patient characteristics for patients included in the matched-pair analysis are shown in Table 6.
Table 6. Patient characteristics*
Characteristic |
Treo |
TBF |
---|---|---|
Median age, years (range) |
58 (18.1–75.7) |
58 (21.2–72.2) |
Median year of transplant (range) |
2019 (2012–2020) |
2019 (2014–2020) |
CR1 at transplant, % |
82 |
82 |
RIC, % |
47 |
47 |
Stem cell source, % |
||
Bone marrow |
13 |
13 |
Peripheral blood |
87 |
87 |
Cytogenetic risk, adverse, % |
16 |
16 |
CR1, first complete remission; RIC, reduced intensity conditioning; TBF, thiotepa-busulfan-fludarabine; Treo, treosulfan. |
Figure 6. 2-year survival outcomes*
aGvHD, acute GvHD; cGvHD, chronic GvHD; GRFS, GvHD-free, relapse-free survival; GvHD, graft-versus-host disease; LFS, leukemia-free survival; NRM, nonrelapse mortality; OS, overall survival; TBF, thiotepa-busulfan-fludarabine; Treo, treosulfan.
*Adapted from Saraceni et al.4
Table 7. Causes of death*
Cause of death, % |
Treo |
TBF |
---|---|---|
Original disease |
41 |
31 |
GvHD |
10 |
31 |
Infection |
31 |
12 |
SOS/VOD |
0 |
6 |
Cardiac toxicity |
3 |
3 |
Other |
16 |
17 |
GvHD, graft-versus-host disease; SOS, sinusoidal obstruction syndrome; TBF, thiotepa-busulfan-fludarabine; Treo, treosulfan; VOD, veno-occlusive disease. |
In summary, treosulfan and TBF based conditioning regimens produced similar outcomes for patients undergoing haploidentical allo-HSCT. Treosulfan-based conditioning may be a valid alternative in AML, although further studies are needed.
Data from the above studies presented at the 48th Annual Meeting of the EBMT, firstly demonstrate the validity of substituting busulfan with fludarabine in standard conditioning regimens in a relapsed/refractory and complete remission setting; secondly, they demonstrate that the substitution of busulfan with treosulfan led to improved survival outcomes for patients in complete remission when combined with fludarabine. Finally, treosulfan-containing regimens are a valid alternative for patients undergoing haploidentical transplant with similar survival outcomes compared with TBF-based conditioning.
Subscribe to get the best content related to MDS delivered to your inbox